Background: To evaluate 106 Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. Methods: From 2007 to 2015, 39 patients were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the mean tumor depth was 3.7 mm (±SD:1.6). Mean dose at the apex of the tumor was 141.4 Gy (± SD: 12.1 Gy). The mean sclera dose was 557.7 Gy (± SD: 257.3 Gy). Results: Mean follow-up was 69.5 months (± SD: 53.8 months). 34 patients (87.1%) remained free of recurrence. In 26 (66.7%) patients a total regression was achieved after a median period of 12 months (Range: 3-60 mon.). By the final examination, the visual acuity of 26 (66.7%) patients was better than 20/200. 12 (30.7%) patients had a visual acuity better than 20/40. Retinopathy was detected in 11 (28.2%) patients. After treatments only 1 (5.1%) patients had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 (10.3%) patients. Cataract development was diagnosed in 21 (53.8%) patients, although 16 (41%) of them had bilateral cataract development. Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5mm or more. There was no significant difference neither in local control (75 % in tumors ≥5mm versus 92.6 % in tumors <5mm) nor in side effects between both groups. Conclusions: Our study proved 106 Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. The data suggest that this treatment is also suitable for tumors with a depth of more than 5mm.
Background: To evaluate 106 Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. Methods: From April 2007 to October 2015, 39 patients with medium sized uveal melanoma were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the mean tumor depth was 3.7 mm (±SD:1.6 mm). The mean dose at the tumor apex was 141.4 Gy (± SD: 12.1 Gy) and 557.7 Gy (± SD: 257.3 Gy) to the sclera. Results: Mean follow-up was 69.5 months (± SD: 53.8 months). Thirty-four patients (87.1%) remained free of recurrence. Twenty-six patients (66.7%) demonstrated a complete tumor regression after a median period of 12 months (3-60 mon.). By the final examination, the visual acuity of 26 patients (66.7%) was better than 20/200, and 12 patients (30.7%) had a visual acuity better than 20/40. Retinopathy was detected in 11 patients (28.2%). After treatments only one patient (5.1%) had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 patients (10.3%). Cataract development was diagnosed in 21 patients (53.8%), and 16 patients (41%) had bilateral cataract development. Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5 mm or more. There was no significant difference in local control or in side effects between both groups observed. Conclusions: Our study proved 106 Ru-brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. Our data suggested that this treatment is also suitable for tumors with a depth of more than 5 mm.
Background: To evaluate 106Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity.Methods: From 2007 to 2015, 39 patients were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the median tumor depth was 3.0 mm (CI: 1.6-8.9 mm). Median dose at the apex of the tumor was 145 Gy (± SD: 12.1Gy). The median sclera dose was 444.0Gy (±SD: 257.3 Gy). Results: Median follow-up was 61.5 months (CI: 8.1-138 mon.). 34 patients (87.1%) remained free of recurrence. In 26 (66.7%) patients a total regression was achieved after a median period of 12 months (CI: 3-60 mon.). By the final examination, the visual acuity of 26 (66.7%) patients was better than 20/200. 12 (30.7%) patients had a visual acuity better than 20/40.Retinopathy was detected in 11 (28.2%) patients. After treatments only 1 (5.1%) patients had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 (10.3%) patients. Cataract development was diagnosed in 21 (53.8%) patients, although 16 (41%) of them had bilateral cataract development.Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5mm or more. There was no significant difference neither in local control (75 % in tumors ≥5mm versus 92.6 % in tumors <5mm) nor in side effects between both groups. Conclusions: Our study proved 106 Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. The data suggest that this treatment is also suitable for tumors with a depth of more than 5mm.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.